1 / 21

Pediatric Psychopharmacology

Pediatric Psychopharmacology. National Institute of Mental Health. Child and Adolescent Treatment and Preventive Intervention Research Branch . Mission:

lilike
Download Presentation

Pediatric Psychopharmacology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pediatric Psychopharmacology National Institute of Mental Health

  2. Child and Adolescent Treatment and Preventive Intervention Research Branch Mission: To promote, conduct, and coordinate federally funded research on the effects of treatment and prevention of mental illness in children and adolescents

  3. Primary Research Questions • What is the efficacy/effectiveness and safety of the most commonly used treatment and preventive interventions? • How current interventions can be improved? • How novel interventions can be developed?

  4. Primary Research Questions • What is the long-term impact of treatments? • How to address treatment non-response? • Which interventions for which patients? • What is the impact of comorbidity? • How do interventions work?

  5. Child and Adolescent Treatment and Preventive Intervention Research Branch

  6. Child and Adolescent Treatment and Preventive Intervention Research Branch

  7. Child and Adolescent Treatment and Preventive Intervention Research Branch Research funding in 1999 (millions): • Prevention $ 18.2 • Psychosocial Tx $ 7.1 • Psychopharm. $ 5.9 • Combined Tx $ 9.3

  8. Child and Adolescent Treatment and Preventive Intervention Research Branch Major areas of funding by disorder (1999, in millions) • Depression $ 8.0 • Anxiety $ 2.6 • ADHD $ 2.5 • Autism $ 2.2

  9. Research • Units • Pediatric • Psychopharmacology Network

  10. Research Units on Pediatric Psychopharmacology • Network of research units devoted to multi-site clinical trials in children • Units are at academic research settings • Main focus is on efficacy and safety of psychotropic medications that are commonly used in children without adequate data • Established in 1996-1997 through competitive contracts

  11. Research Units on Pediatric Psychopharmacology Columbia University L. Greenhill, M.D. Johns Hopkins University M. Riddle, M.D. Pittsburgh University B. Birmaher, M.D. Yale University F. Volkmar, M.D. UCLA J. McCracken, M.D. Indiana University C. McDougle, M.D. Ohio State University M. Aman, Ph.D.

  12. Research Units on Pediatric Psychopharmacology • Each RUPP has experts in child psychiatry, psychopharmacology, pediatrics, clinical trial design and methods • Data management center • Network statistician • The network as a resource available to potential sponsors of clinical trials in children (e.g., NIH, industry, private foundations)

  13. Research Units on Pediatric Psychopharmacology NIMH supports: • Basic infrastructure for the units • Data management center • Specific protocols in areas that are: • Of public health importance • Not funded, or unlikely to be funded through grant mechanisms • Not sponsored by industry

  14. Research Units on Pediatric Psychopharmacology Some Multisite Protocols: • SSRI for Children with Anxiety Disorders • Risperidone for Children with Autism and Behavioral Disturbances • SSRI for Depressed Children with Bipolar Disorder • Sequential Treatments for Children with Comorbid ADHD and Anxiety Disorders

  15. TADS Treatment for Adolescents with Depression Study

  16. Primary Aims • To compare the effectiveness of FLX, CBT, COMB, and PBO for reducing MDD symptoms and patient disability acutely. • To compare the effectiveness of the three active treatments (FLX, CBT, and COMB) during long-term treatment. • To compare the speed of response of FLX, CBT and COMB.

  17. TADS • N=432 • Age: 12-17 years • Dx: major depression • Design: parallel-group • Tx: Med, CBT, CBT+Med, Placebo • Sites: 10

  18. Stages of Treatment Model • Stage I: Acute treatment for 12 weeks • Stage II: Consolidation for 6 weeks • Stage III: Maintenance for 18 weeks • Stage IV: One year open follow-up

  19. Recently Funded Grants • Relapse prevention in youths with depression • Treatment of SSRI-resistant depression in adolescents • Mood stabilizers for youths with bipolar • Efficacy and safety of methylphenidate in preschoolers with ADHD

  20. Preschool ADHD Treatment Study Age 3-5 yrs (N=198) vs. Age 6-8 yrs (N=66) Screening/evaluation 8 weeks Open titration 3 weeks Placebo-controlled trial 12 weeks Open maintenance 10 months Blinded discontinuation 6 weeks

  21. Some areas in need of expansion • Schizophrenia and other psychoses • Bipolar • Depression in prepubertal children • Autism • Comorbid conditions

More Related